Phase 3 PEGASUS study shows substantial haematological response in patients treated with investigational targeted C3 therapy pegcetacoplan – for paroxysmal nocturnal haemoglobinuria

Study shows 70.7% of pegcetacoplan-treated patients (29/41) vs. 5.1% of eculizumab (C5 inhibitor)-treated patients (2/39) achieved a good, major or complete haematologic response (p<0.0001) at 16 wks, which meant reaching a level of mild or no anaemia & not requiring transfusions

Biospace Inc.